SHANGHAI, Sept. 03, 2025 – Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a prominent provider of AI-driven Internet healthcare solutions, has announced that its technology team will engage in a collaborative National Natural Science Foundation of China (NSFC) project. This initiative, led by Professor Liang Jianping of Sun Yat-sen University, marks the company’s second research partnership supported by the NSFC.

The forthcoming study will explore the impact of human-AI collaboration models on consumer adoption. Fangzhou, participating as the project’s sole corporate partner, will concentrate on the “AI + chronic disease management.” It will work closely with the research team to investigate how human–AI collaboration influences consumer uptake of healthcare products and services, while also providing crucial support for real-world data collection and model optimization. The project seeks to deepen academic insights into AI and cognitive science, alongside accelerating the broader integration of AI in healthcare.

Previously, in 2024, Fangzhou contributed to an NSFC project focused on AI supervision and online consumer behavior, which was spearheaded by Professor Wang Haizhong from Sun Yat-sen University. These two engagements underscore Fangzhou’s proactive role in fostering industry-academia collaboration and emphasize its dedication to advancing technical expertise and strengthening AI innovation within the healthcare sector.

Dr. Xie Fangmin, Fangzhou’s founder, chairman, and CEO, commented, “Our continued involvement in NSFC projects demonstrates that Fangzhou is not merely achieving commercial success through AI-driven healthcare but also making significant contributions to China’s wider innovation agenda.”

China has designated artificial intelligence as a strategic national priority, with the State Council recently issuing guidelines to promote the “AI+” initiative across six critical fields, including healthcare. The recent NSFC approvals are aligned with this national strategy by addressing the adoption of AI-enabled products and services by consumers.

Fangzhou has made substantial investments in cultivating research talent and fostering AI innovation. The “H2H Smart Healthcare Ecosystem,” developed by Fangzhou’s technology team, was recognized among Guangzhou’s leading “AI+” solutions in 2024. Furthermore, the Company has established a comprehensive talent development system, focused on building a cross-disciplinary team that integrates academic knowledge with industry expertise, thereby facilitating both professional growth and valuable societal contributions.

Fangzhou plans to continue strengthening its participation in national research initiatives and to develop integrated industry–academia–research innovation platforms. The ultimate goal is to translate pioneering academic achievements into practical public healthcare services and contribute to the objectives of “Healthy China 2030.”

About NSFC Major Research Program
The National Natural Science Foundation’s Major Research Program is its most esteemed and extensively funded initiative. It is designed to address national strategic requirements and scientific frontiers by consolidating top resources to enhance China’s capacity for original research and support its economic and social advancement.

About Fangzhou Inc.
Fangzhou Inc. (06086.HK) stands as China’s premier online platform for chronic disease management, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025. The Company specializes in delivering customized medical care and precision medicine solutions. For more information, please visit .

Media Contact
For further inquiries or to arrange interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements